The FDA has approved Zepatier for the treatment of HCV genotypes 1 and 4 infections. Zepatier has been approved by the FDA to treat hepatitis C virus genotypes 1 and 4 infections in adult patients.

(PRINCETON, N.J., OCTOBER 15, 2015) – Bristol-Myers Squibb (NYSE:BMY) today announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in ...

May 24, 2011 (Chicago, Illinois) — The direct-acting protease inhibitor telaprevir, given in combination with pegylated interferon plus peginterferon/ribavirin (PR), increased the chance of sustained ...

Moreno et al. investigated the therapeutic potential of TMC435—an NS3/4a protease inhibitor—for patients infected with HCV genotypes 2–6 (TMC435 is already in phase III development for patients with ...

Please provide your email address to receive an email when new articles are posted on . LONDON — Although the annual incidence of acute hepatitis C virus has decreased over the past 10 years in ...

Please provide your email address to receive an email when new articles are posted on . Treatment with direct-acting antivirals was associated with reduced risk for extrahepatic manifestations among ...

MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...

April 11, 2011 (Berlin, Germany) — Pegylated interferon lambda (Peg-IFN lambda) showed virological responses superior to the standard of care, pegylated interferon alfa-2a (Peg-IFN alfa-2a), when ...

Sovaldi (sofosbuvir) is a prescription drug that’s used to treat hepatitis C. Sovaldi comes in the form of tablets and pellets, both of which you take by swallowing. Sovaldi is prescribed to adults ...

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients ...